Study of Resmetirom in Children and Adolescents With MASH
← catalyst calendarNCT07763015 · readout ≤ 1,077 d
Sponsored by Madrigal Pharmaceuticals, Inc. (industry) · MDGL — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
61estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- MASH
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention
- Drug: Resmetirom
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability of multiple ascending doses of resmetirom
measured Baseline through approximately Day 21 (or the protocol-defined safety follow-up period)
Permalink · MDGL's whole pipeline · Catalyst calendar · Every registered study · What changed